Forest Ray

Premium Save for later NEW YORK – Despite strong provider demand and improving payor coverage driven by biomarker testing laws being passed around the US, a recent decision by UnitedHealthcare to drop coverage of multi-gene pharmacogenomics testing has cast uncertainty on Myriad Genetics' future revenue projections.

Premium Save for later NEW YORK – Six months after incoming CEO Brian Blaser suspended guidance to thoroughly review the business, QuidelOrtho has resumed offering an outlook to investors. The in vitro diagnostics and lab test maker elaborated on in-process restructuring it believes will support long-term profitability on a call to discuss third quarter earnings on Thursday after the close of the market.

NEW YORK – 23andMe said on Tuesday that its fiscal second quarter revenues fell 12 percent year over year a day after announcing a massive restructuring that will cut its workforce by 40 percent.

NEW YORK – The United Arab Emirates last month launched a mandatory national premarital genetic screening program, in which all Emiratis seeking to wed will be required to be screened for over 840 autosomal recessive diseases.

NEW YORK – Although polygenic risk scores for coronary heart disease (CHD) have attracted keen interest and are moving towards becoming clinically

NEW YORK – Empress Therapeutics sees the next wave of small-molecule medicines reflected in the drug-like behavior of metabolites produced by the human microbiome.

NEW YORK – Polygenic risk scores (PRS) inched closer to clinical adoption over the past year, with several studies demonstrating their clinical utility and feasibility of implementing them into clinical workflows.

NEW YORK – Epigenetics company Volition sees a path towards expansion into East Asian markets, beginning with Taiwan, following the publication of

NEW YORK – Enrollment recently began for a prostate cancer screening program sponsored by the Veterans Administration aimed at determining whether genetic testing can improve prostate cancer screening.